emilimogene sigulactibac
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2022 (NCT05608187)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095118 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05608187 | Phase 2 | Sep 26, 2022 | European Commission, Ilya Pharma, Skåne University Hospital |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Commission | Government | 1 | 0 | 1 | 2022 |
| Ilya Pharma | For profit | 1 | 1 | 1 | 2022 |
| Skåne University Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1